Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

Abstract While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor–positive/human epidermal growth factor receptor 2‒negative metastatic breast cancer, further mechanistic insights are ne...

Full description

Bibliographic Details
Main Authors: Zhou Zhu, Nicholas C. Turner, Sherene Loi, Fabrice André, Miguel Martin, Véronique Diéras, Karen A. Gelmon, Nadia Harbeck, Cathy Zhang, Joan Q. Cao, Zhengming Yan, Dongrui R. Lu, Ping Wei, Todd L. VanArsdale, Paul A. Rejto, Xin Huang, Hope S. Rugo, Sibylle Loibl, Massimo Cristofanilli, Richard S. Finn, Yuan Liu
Format: Article
Language:English
Published: Nature Portfolio 2022-08-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-022-00297-1

Internet

https://doi.org/10.1038/s41698-022-00297-1

Similar Items